Genadieva-Stavrik, S;
Boumendil, A;
Dreger, P;
Peggs, K;
Briones, J;
Corradini, P;
Bacigalupo, A;
... Sureda, A; + view all
(2016)
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Annals of Oncology
, 27
(12)
pp. 2251-2257.
10.1093/annonc/mdw421.
Preview |
Text
Peggs_RIC vs MAC in RR HL - 07082016.pdf - Accepted Version Download (799kB) | Preview |
Abstract
BACKGROUND: To evaluate long-term outcome of myeloablative allogeneic stem cell transplantation (allo-SCT) (MAC) versus reduced-intensity allo-SCT (RIC) in patients with relapsed/refractory Hodgkin's lymphoma (HL) in recent years. PATIENTS AND METHODS: A total of 312 patients (63 MAC and 249 RIC) with relapsed/refractory HL who received allo-SCT between 2006 and 2010 and were reported to the EBMT Database were included in the study. RESULTS: With a median follow-up for alive patients of 56 (26–73) months, there were no significant differences in non-relapse mortality (NRM) between MAC and RIC. Relapse rate (RR) was somewhat lower in the MAC group (41% versus 52% at 24 months, P = 0.16). This lower RR translated into a marginal improvement in event-free survival (EFS) for the MAC group (48% versus 36% at 24 months, P = 0.09) with no significant differences in overall survival (73% for MAC and 62% for RIC at 24 months, P = 0.13). Multivariate analysis after adjusting for disease status at the time of allo-SCT showed that the use of MAC was of borderline statistical significance for predicting a lower RR and EFS [HR 0.7, 95% CI (0.5–1.0), P = 0.1] and [HR 0.7, 95% CI (0.5–1.0), P = 0.07], respectively, after allo-SCT. CONCLUSIONS: With modern transplant practices, the NRM associated with MAC for HL has strongly decreased, resulting into non-significant improvement of EFS because of a somewhat better disease control compared with RIC transplants. The intensity of conditioning regimens should be considered when designing individual allo-SCT strategies or clinical trials in patients with relapsed/refractory HL.
| Type: | Article |
|---|---|
| Title: | Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/annonc/mdw421 |
| Publisher version: | http://doi.org/10.1093/annonc/mdw421 |
| Language: | English |
| Additional information: | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Oncology, relapsed/refractory Hodgkin's lymphoma, allogeneic stem cell transplantation, conditioning regimen, BRENTUXIMAB VEDOTIN, FREE SURVIVAL, DISEASE, CHEMOTHERAPY, IDENTIFICATION, RECURRENT, THERAPY, SOCIETY, TRIAL, ALLO |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1539880 |
Archive Staff Only
 |
View Item |
